Amino Minder Brings Real Pharmacokinetic Modeling to Peptide and GLP-1 Tracking, Now Live on the Web -- Android App Coming Soon
Original HTML

Amino Minder Brings Real Pharmacokinetic Modeling to Peptide and GLP-1 Tracking, Now Live on the Web -- Android App Coming Soon

New tracker goes beyond dose logging to model estimated plasma levels over time, including downstream hormone cascades for GH-secretagogue stacks

KINGMAN, Ariz., Sept. 8, 2026 /PRNewswire/ -- Baya Lobo LLC today announced the web launch of Amino Minder (aminominder.com), a peptide, GLP-1, TRT, and HRT protocol tracker built around a feature no competing app currently claims: a real pharmacokinetic (PK) engine that estimates and graphs a user's plasma level for each tracked compound over time, rather than simply logging that a dose was taken.

Most peptide-tracking apps on the market function as digital logbooks — a calendar of doses, reminders, and inventory. Amino Minder's PK engine goes further, using standard one-compartment absorption/elimination modeling to show users a rise-and-decay curve for every compound they log, adjustable for route of administration, individual half-life, and a user-configurable clearance modifier. For compounds like the GHRH- and GHRP-class growth-hormone secretagogues — where the injected peptide triggers a downstream cascade of natural GH release, which in turn drives a separate, slower IGF-1 response — Amino Minder models that full chain, including synergy effects when GHRH- and GHRP-class compounds are stacked together, a combination known to produce a greater GH response than either compound alone.

"When I started my peptide journey, I couldn't find the app I wanted, at any cost. So we built it, and made it affordable," said Jim Hamilton, founder of Baya Lobo LLC.

Additional features include pre-built multi-compound stack templates (including commonly-used combinations like GLOW, KLOW, and Wolverine), a low-clutter inventory tracker, streaks and milestone tracking to support consistency, customizable dose reminders, and a polished PDF export designed to be shared with a doctor or research partner. Consistent with its position as an informational tracking tool — not a source of medical advice — Amino Minder deliberately does not include an AI chat assistant or any feature that suggests dosing decisions to users.

Amino Minder is priced at $1.99/month, $9.99/year, or $24.99 as a one-time lifetime purchase — undercutting every comparable app in the category, and one of the only ones offering a straightforward lifetime tier with no retroactively-added sub-tiers.

The web app is available now at aminominder.com. An Android app is in final preparation for Google Play, with iOS to follow.

About Amino Minder

Amino Minder is a product of Baya Lobo LLC, based in Kingman, Arizona. Amino Minder is intended for personal tracking and informational purposes only. It is not a medical device and does not provide medical advice.

Media Contact

Jim Hamilton

Baya Lobo LLC

[email protected]

(928)473-1591

SOURCE Amino Minder

Share this article

Class (B2B/B2C)
B2C
Ingest Status
Rewritten
Dedupe hash
84dc01285e7e89e6f5f6da6d9e6f5a83
Press Eligible
Yes
Press Eligible Reason
Consumer health tracking app launch featuring pharmacokinetic modeling, pricing, and upcoming mobile availability.
Source Name
Unknown Company
Original Summary

<p>New tracker goes beyond dose logging to model estimated plasma levels over time, including downstream hormone cascades for GH-secretagogue stacks KINGMAN, Ariz., Sept. 8, 2026 /PRNewswire/ -- Baya Lobo LLC today announced the web launch of Amino Minder (aminominder.com), a peptide, GLP-1,...</p>